Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
UNIVERSITE D'AIX-MARSEILLE has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. LORA E BARNHART DRISCOLL is the busiest examiner, managing 1 pending office action. The distribution across different examiners and art units suggests a diverse range of inquiries.
The presence of 2 distinct examiners for 2 pending office actions means that each case is being reviewed by a different person. Furthermore, the involvement of 2 distinct art units indicates that the technical subject matter within the Biotechnology & Pharmaceuticals area is varied enough to be assigned to different specialized groups. LORA E BARNHART DRISCOLL is one of the 2 examiners, and her 1 pending office action is part of the university's current pending workload.
For a practitioner, this data shows that the university's prosecution is not centralized. Each of the 2 pending office actions requires a unique approach tailored to a specific examiner and a specific art unit. The diversity in art units suggests that the biotechnology being patented covers different sub-sectors, requiring a broad understanding of different examination standards. The involvement of 2 distinct art units and 2 distinct examiners provides multiple points of contact within the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, LORA E BARNHART | 1 | 32.0% | +20.0% |
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18355451 | TAFA4 Compounds and Uses Thereof for Treating Pain | DRISCOLL, LORA E BARNHART | 27d |
| 18339781 | TRANSFERRIN RECEPTOR-BINDING MOLECULES, CONJUGATES THEREOF AND THEIR USES | TAYLOR, LIA ELAN | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18355451 | TAFA4 Compounds and Uses Thereof for Treating Pain | DRISCOLL, LORA E BARNHART | 3991 | §112Other | Final Rejection | 27d | Pending | Jul 20, 2023 |
| 18339781 | TRANSFERRIN RECEPTOR-BINDING MOLECULES, CONJUGATES THEREOF AND THEIR USES | TAYLOR, LIA ELAN | 1641 | §112Other | Final Rejection | — | Pending | Jun 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial